STABLE COMPOSITIONS CONTAINING N-PROPARGYL-1-AMINOINDAN

Abstract: A pharmaceutical composition comprising as active ingredient a racemic, S(-), and R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof, and at least 60 % by weight of at least one pentahydric or hexahydric alcohol. Optionally the composition may contain citric acid and magnesium stearate.

Description: STABLE COMPOSITIONS CONTAINING N-PROPARGYL-1- AMINOINDAN FIELD OF THE INVENTION The present invention concerns formulations of racemic, S(-) or R(+) enantiomers of N-propargyl-1-aminoindan, and especially formula¬ tions of the enantiomer R(+) of N-propargyl-1-aminoindan (referred to hereinafter as R(+) PAl) which is a selective irreversible inhibitor of the B- for of the enzyme monoamine oxidase used, for example, for the treatment of Parkinson's disease. In the following the enzyme monoamine oxidase will be referred to as MAO and the B-form thereof as MAO-B. BACKGROUND OF THE INVENTION GB 1 003 686 discloses a group of benzocycloalkane compounds in which the cycloalkane has from five to seven ring members and is substituted by an N-(alkynylalkyl)amino group, and their use as MAO inhibitors. The patent further discloses the use of the subject compounds in admixture with a variety of substances including various alcohols such as a benzyl alcohol, stearyl alcohol, and methanol. The patent, however, does not teach how and by what criteria any of the many possible carriers and other ingredients arc selected so as to overcome the stability problem of the product. _ *" > _ The object of the present invention is to provide stable formula¬ tions comprising an effective amount of racemic, S(-) or R(+)-N-proparg- yl-1-aminoindan. For the sake of simplicity, the abbreviation PAl, unless specified otherwise, will be used to denote the enantiomers of N-propargyl- 1-aminoindan, as well as their racemic mixtures. SUMMARY OF THE INVENTION In accordance with the invention it was suφrisingly found that the stability of formulations comprising PAl can be significantly improved by the incorporation of relatively large amounts of certain alcohols. In accordance with the present invention there is provided a pharmaceutical composition comprising as an active ingredient a therapeuti¬ cally effective amount of a compound being a member selected from the group of racemic, S(-), and R(+)-N-propargyl-l-aminoindan or a pharmaceutically acceptable salt thereof, and at least 60% by weight of at least one alcohol being a member selected from the group of pentahydric and hexahydric alcohols. In a preferred embodiment of the present invention the active ingredient is R(+)-N-propargyl-l-aminoindan. Preferably the composition comprises at least 70% of said at least one alcohol. Typically the alcohol used in accordance with of the invention, is a member selected from the group of mannitol, xylitol and sorbitol. In accordance with the invention the PAI-comprising composition may further include citric acid, preferably in an amount of 0.5 to 2% by weight. If desired, compositions according to the invention may further comprise magnesium stearate, preferably in an amount of 0.1 to 0.5% by weight. According to this embodiment, where the amount of said at least one alcohol is less than 70% by weight, the composition further comprises citric acid in an amount specified above. Where the amount of said at least one alcohol is at least 70% by weight, the inclusion of citric acid is optional. The composition of the present invention may optionally also include conventional additives such as fillers, lubricants, disintegrants, glidants, flavoring agents, sweeteners, coloring agents, and the like, all as known per se. Examples of fillers which may be used in accordance with the present invention are lactose, starch, microcrystalline cellulose, maltrin and the like. The compositions of the present invention may be prepared by methods known per se, familiar to those skilled in the art. For example, PAl and all other ingredients (with the exception of the lubricant, when used) may be screened and mixed thoroughly in a suitable granulating machine. The granulation may occur in the presence of purified water, following which the composition is dried. The dry granulate may then be milled, lubricated and compressed into tablets. R(+) PAl itself may be prepared, for example, according to the process described in Example 6B of WO95/11016. The following non-limiting examples are given by way of illustration. EXAMPLES EXAMPLE 1 mg/tablet R(+)-N-propargyl-l-aminoindan mesylate 3.12 Mannitol 62.5 Maltodextrin (Maltrin 150) 36.0 Croscarmellose sodium (Ac-Di-Sol) 2.1 Talc 1.5 EXAMPLE 2 mg/tablet R(+)-N-propargyl-l-aminoindan mesylate 1.56 Mannitol 79.14 Starch 10.0 Pregelatinized starch 10.0 Colloidal silicon dioxide 0.6 Talc 2.0 Stearic acid 2.0 EXAMPLE 3 mg/tablet R(+)-N-propargy 1- 1 -aminoindan mesylate 3.12 Mannitol 76.58 Starch 10.0 Pregelatinized starch 10.0 Colloidal silicon dioxide 0.6 Citric acid 1.0 Talc 2.0 EXAMPLE 4 mg/tablet R(+)-N-propargyl- 1 -aminoindan mesylate 3.12 Mannitol 69.88 Lactose (hydrous) 14.0 Starch 14.0 Glyceryl Behenate (Compitrol 888 ATO) 2.0 - EXAMPLE 5 mg/tablet R(+)-N-propargyl-l -aminoindan mesylate 3.12 Mannitol 77.28 Starch 10.0 Starch STA-RX 1500 10.0 Colloidal silicon dioxide, Aerosil 0.6 Hydrogenated vegetable type I (Sterotex Dritex) 2.0 EXAMPLE 6 In order to compare the compositions of the present invention with those known in the prior art, two of the above formulations were compared with a formulation described in WO95/11016. Formulation of WO95/11016 (Example 201 mg/tablet R(+)-N-propargyl-l-aminoindan HCl 1.56 Lactose (hydrous) 50.0 Pregelatinized starch 36.0 Microcrystalline cellulose 14.0 Sodium starch glycolate 2.14 Talc 1.0 Magnesium stearate 0.5 This formulation, as well as those described under Examples 2 and 3 of the present application were subjected to 6 months at 40°C and 75% humidity. The percentage of degradants of the active material was assayed at the end of the six month period. The following procedure was adopted to determine the degrada¬ tion of the formulations prepared. The tablets were finely powdered and extracted with a diluent such as a mixture of water, acetonitrile and perchloric acid. An aliquot of the extraction product was injected into an HPLC and eluted using the same mixture as said diluent mixture. The area corresponding to the PAl compound was determined as was that of any other major peak. The calculations of degradation percent was made by comparing the areas of the measured peaks with those obtained from the standard preparation. It was found that the formulation prepared according to the disclosure of Example 20 of WO95/11016 contained after storage 3.08% degradants whereas the formulations of Examples 2 and 3 contained 0.51% and less than 0.1% degradants, respectively. EXAMPLE 7 Formulations according to the present invention and others according to the description given in Example 20 of WO95/11016 were prepared containing the ingredients shown in Table 1. The formulations described in this Table are designated "PCT" when prepared in accordance with the disclosure in WO95/11016, or by a number which corresponds to the number of the Example in the present application, in which they are described. The qualifying symbols of A, B, C or D appearing next to some of these designations denote certain variations in said formulations. The percentage of degradation, presented in Table 2, was calculated for all the formulations of Table 1, after storing them for 1 month at 55°C or for 6 months at 40°C and 75% humidity. Those formulations stored according to the latter storing conditions are marked in the Table with an astrix (*). As can be seen from Table 2, the stabilities of all the compositions of the present invention was superior to those of the prior art.

Claims: CLAIMS: 1. A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a compound being a member selected from the group of racemic, S(-), and R(+)-N-propargyl-l -aminoindan or a pharmaceuti¬ cally acceptable salt thereof, and at least 60% by weight of at least one alcohol being a member selected from the group of pentahydric and hexahydric alcohols. 2. A pharmaceutical composition according to Claim 1 , comprising at least 70% by weight of said at least one alcohol. 3. A pharmaceutical composition according to Claim 1 or 2, wherein the said at least one alcohol is a member selected from the group of mannitol, xylitol and sorbitol. 4. A pharmaceutical composition according to any one of claims 1 to 3, further comprising citric acid. 5. A pharmaceutical composition according to Claim 4, wherein the amount of citric acid is 0.5 to 2% by weight. 6. A pharmaceutical composition according to any one of claims 1 to 5, further comprising magnesium stearate. 7. A pharmaceutical composition according to Claim 6, wherein the amount of magnesium stearate is 0.1 to 0.5% by weight. 8. A pharmaceutical composition according to Claim 6 or 7 in which the amount of said at least one alcohol is 70% or less, further comprising citric acid. 9. A pharmaceutical composition according to any one of the preceding claims, wherein said active ingredient is R(+)-N-propargyl-l-aminoindan.

Inventors: BERGER PESKIN TIRTSAH, CACIULARU FANNY, BERGER PESKIN, TIRTSAH, CACIULARU, FANNY
Applicants: BERGER PESKIN TIRTSAH, CACIULARU FANNY, TEVA PHARMA, BERGER PESKIN, TIRTSAH, CACIULARU, FANNY, TEVA PHARMACEUTICAL INDUSTRIES LTD.
Application year: 1996
Main classification: A61K
IPC codes: A61K9, A61K31, A61P25